Ubs Asset Management Americas Inc Altimmune, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 4,215 shares of ALT stock, worth $17,155. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,215
Previous 106,872
96.06%
Holding current value
$17,155
Previous $534,000
97.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ALT
# of Institutions
213Shares Held
36MCall Options Held
4.92MPut Options Held
4.18M-
Black Rock Inc. New York, NY5.32MShares$21.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.17MShares$21 Million0.0% of portfolio
-
State Street Corp Boston, MA2.75MShares$11.2 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$11.2 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA1.93MShares$7.87 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $200M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...